Global Mammalian Polyclonal IgG Antibody Market Size Likely to Expand at a CAGR of 4.8% By 2033

As per the current market research conducted by the CMI Team, the global Mammalian Polyclonal IgG Antibody Market size is expected to record a CAGR of 4.8% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 2,272.6 Million. By 2033, the valuation is anticipated to reach USD 3,465.6 Million.

Mammalian Polyclonal IgG Antibody Market: Growth Factors and Dynamics

• Increasing Demand in Research and Diagnostics: The growing demand for mammalian polyclonal IgG antibodies in research, diagnostics, and therapeutics is a significant growth factor. These antibodies are widely used in various applications, including Western blotting, ELISA, immunohistochemistry, and flow cytometry, driving market expansion.

• Rising Incidence of Chronic Diseases: The rising incidence of chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, fuels the demand for antibodies for disease diagnosis, monitoring, and treatment. Mammalian polyclonal IgG antibodies play a crucial role in detecting disease biomarkers and developing targeted therapeutics, contributing to market growth.

• Advancements in Biotechnology: Technological advancements in biotechnology, including recombinant DNA technology, hybridoma technology, and phage display technology, have facilitated the production of high-quality mammalian polyclonal IgG antibodies. These advancements enable efficient antibody generation, purification, and customization, driving market expansion.

• Expanding Biopharmaceutical Industry: The expanding biopharmaceutical industry, coupled with increasing investment in biologics research and development, boosts demand for mammalian polyclonal IgG antibodies as critical reagents in drug discovery and development. The rise in biopharmaceutical R&D activities, particularly in monoclonal antibody therapeutics, stimulates market growth.

• Growing Research Funding: The availability of research funding from government agencies, academic institutions, and private organizations supports research projects and initiatives involving mammalian polyclonal IgG antibodies. Funding for basic and translational research in areas such as cancer biology, immunology, and infectious diseases drives market growth by fostering innovation and collaboration.

• Strategic Collaborations and Partnerships: Collaborations and partnerships between academic institutions, biotechnology companies, and pharmaceutical firms play a vital role in driving innovation and commercialization of mammalian polyclonal IgG antibodies. Strategic alliances facilitate technology transfer, resource sharing, and product development, accelerating market growth and market penetration.

Mammalian Polyclonal IgG Antibody Market: Partnership and Acquisitions

• In 2023, Murron secured a patent for its drug composition, IMM-529, a polyclonal antibody targeting Clostridioides difficile infections, from the European regulatory authority. This grants the company a competitive advantage. Additionally, regional expansion is a key strategy adopted by many market participants.

• In 2022, ProteoGenix launched the “XtenCHO Transient Expression System,” simplifying recombinant protein production and expediting early drug screening phases. This system encompasses antibodies from various species, isotopes, and formats, enhancing versatility and efficiency in biologics development and discovery processes.

Report Scope

Mammalian Polyclonal IgG Antibody Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Mammalian Polyclonal IgG Antibody Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Supply Chains: The COVID-19 pandemic disrupted global supply chains, leading to shortages of raw materials, reagents, and equipment necessary for the production of mammalian polyclonal IgG antibodies. Delays in manufacturing and distribution hindered market growth and impacted research and diagnostic activities.

• Shift in Research Priorities: The focus of research efforts shifted towards COVID-19 diagnostics, vaccines, and therapeutics, diverting resources and attention away from other areas of research, including mammalian polyclonal IgG antibody development. Reduced funding and demand for non-COVID-19-related research projects further affected market dynamics.

• Resumption of Research Activities: With the easing of pandemic restrictions and the gradual reopening of laboratories and research facilities, there is a gradual resumption of research activities related to mammalian polyclonal IgG antibodies. Researchers and companies are returning to pre-pandemic research projects, contributing to market recovery.

• Diversification of Product Offerings: Companies are diversifying their product offerings beyond COVID-19-related products to include mammalian polyclonal IgG antibodies for other research and diagnostic applications. Expanding product portfolios and addressing diverse customer needs help mitigate the impact of the pandemic and drive market recovery.

• Investment in Biomanufacturing Infrastructure: Investments in biomanufacturing infrastructure and capacity expansion initiatives enable companies to meet the growing demand for mammalian polyclonal IgG antibodies. Building robust manufacturing facilities and supply chain resilience enhances market readiness and accelerates recovery.

• Collaborative Research Efforts: Collaborative research efforts between academia, industry, and government agencies facilitate knowledge exchange, technology transfer, and innovation in mammalian polyclonal IgG antibody research. Strategic partnerships and consortia drive research advancements and stimulate market recovery.

• Rising Demand for Research Tools: The increasing demand for research tools and reagents in areas such as immunology, oncology, and infectious diseases drives market recovery for mammalian polyclonal IgG antibodies. As research activities resume and intensify, there is a corresponding uptick in demand for antibodies for research and diagnostic purposes.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Mammalian Polyclonal IgG Antibody Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Mammalian Polyclonal IgG Antibody Market:

• Thermo Fisher Scientific Inc.
• Abcam plc
• Bio-Rad Laboratories Inc.
• Merck KGaA (Sigma-Aldrich Corporation)
• Santa Cruz Biotechnology Inc.
• Cell Signaling Technology Inc.
• R&D Systems Inc. (a Bio-Techne brand)
• Agilent Technologies Inc.
• GenScript Biotech Corporation
• Boster Biological Technology
• Proteintech Group Inc.
• Enzo Life Sciences Inc.
• OriGene Technologies Inc.
• RayBiotech Inc.
• Rockland Immunochemicals Inc.
• Others

The Mammalian Polyclonal IgG Antibody Market is segmented as follows:

By Type

• Goat
• Rabbit
• Horse
• Mouse
• Others

By Product

• Cardiac Markers
• Metabolic Markers
• Renal Markers
• Others

By Application

• ELISA
• Immunoturbidometry
• Immunoelectrophoresis
• Antibody Identification
• Immunohistochemistry
• Immunocytochemistry
• Western Blotting
• Others

By End Users

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)
• Diagnostic Laboratories
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America